Certara (NASDAQ:CERT) Stock Price Down 4.2% – Here’s Why

Shares of Certara, Inc. (NASDAQ:CERT) were down 4.2% on Tuesday . The stock traded as low as $13.80 and last traded at $13.80. Approximately 573,449 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 1,155,880 shares. The stock had previously closed at $14.40.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. William Blair reiterated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Barclays cut their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Robert W. Baird upped their price target on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Certara presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Certara Price Performance

The firm has a 50 day moving average price of $11.61 and a 200 day moving average price of $11.39. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $2.23 billion, a PE ratio of -69.15, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERT. Versant Capital Management Inc lifted its position in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after acquiring an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC grew its position in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Certara in the fourth quarter valued at $47,000. Finally, Blue Trust Inc. raised its position in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.